Plain-English translation of NCT06515899 on ClinicalTrials.gov ā Ā· Source last updated Ā· Translation generated Ā· How we translate trials
This trial studied haemodiafiltration (HDF), a type of kidney dialysis treatment, to understand how well it removes harmful middle-sized toxins from the blood. Researchers wanted to learn whether the benefit of this treatment came from better removal of these toxins, improved blood pressure control, or reduced inflammation. The study observed patients already receiving this treatment to measure how much toxin removal occurred during their routine dialysis sessions.
Large studies have shown that patients using this dialysis technique with higher treatment volumes lived longer, but doctors didn't fully understand why. Understanding the connection between treatment volume and toxin removal could help improve how dialysis is prescribed and monitored.
Participants attended a single study visit during one of their regular dialysis sessions. During this visit, researchers recorded standard clinical information and measured the dialysis treatment settings. Blood samples were taken at the start and end of the dialysis session to measure how well the treatment removed harmful toxins from the blood.
AI-generated summary from trial data Ā· Jul 12, 2026 Ā· Not medical advice
United Kingdom
Enrollment target
~342 participants
Started
January 2024
Primary completion
July 2025
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.